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Abstract
Background: It has been reported that oral anticoagulation (OAC) is underused among Chinese patients with non-
valvular atrial fibrillation (NVAF). Non-vitamin K antagonist oral anticoagulants (NOAC) have been recommended by
recent guidelines and have been covered since 2017 by the Chinese medical insurance; thus, the overall situation
of anticoagulant therapy may change. The aim of this study was to explore the current status of anticoagulant
therapy among Chinese patients with NVAF in Jiangsu province.
Methods: This was a multi-center, cross-sectional study that was conducted in seven hospitals from January to
September in 2017. The demographic characteristics and medical history of the patients were collected by
questionnaire and from the medical records. Multivariate logistic regression was used to identify factors associated
with anticoagulant therapy.
Results: A total of 593 patients were included in the analysis. A total of 35.6% of the participants received OAC
(11.1% NOAC and 24.5% warfarin). Of those patients with a high risk of stroke, 11.1% were on NOAC, 24.8% on
warfarin, 30.6% on aspirin, and 33.6% were not on medication. Self-paying, duration of AF ≥5 years were negatively
associated with anticoagulant therapy in all patients (OR 1.724, 95% CI 1.086~2.794; OR 1.471, 95% CI 1.006~2.149,
respectively), whereas, permanent AF was positively associated with anticoagulant therapy (OR 0.424, 95% CI
0.215~0.839). Among patients with high risk of stroke, self-paying and increasing age were negatively associated
with anticoagulant therapy (OR 2.305, 95% CI 1.186~4.478; OR 1.087, 95% CI 1.041~1.135, respectively).
Conclusions: Anticoagulant therapy is positively associated with permanent AF and negatively associated with self-
paying, duration of AF > 5 years. Furthermore, the current status of anticoagulant therapy among Chinese patients
with NVAF in Jiangsu province does not appear optimistic. Therefore, further studies should focus on how to
improve the rate of OAC use among NVAF patients. In addition, policy makers should pay attention to the
economic situation of the patients with NVAF using NOAC.
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Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia in clinical practice. It has been reported that
the prevalence of AF in the elderly Chinese population
was 1.8% [1]. With an increasingly aging population and
the incidence of AF-related risk factors, this number is
expected to rise. It was predicted that there would be 5.2
million men and 3.1 million women aged > 60 years with
AF in China by 2050 [2], which will be a major social
health problem. AF is an independent risk factor for
stroke, and AF-related stroke accounts for 20% of all
strokes [3, 4]. Apart from this, AF is independently asso-
ciated with a 2-fold increased risk of all-cause mortality
in women and a 1.5-fold increase in men [5–7], impos-
ing a considerable medical burden on individuals and
health care systems.
A cornerstone of the management AF is to prevent
AF-related stroke and systemic embolism. Recently,
some major guidelines have recommended oral anticoa-
gulation (OAC) for patients with non-valvular atrial
fibrillation (NVAF), especially those at moderate to high
risk of thromboembolism based on CHA2DS2−VASC
scores, for reducing risk of stroke [8, 9]. Currently, OAC
used in clinical practice include vitamin K antagonists
(VKAs, e.g., warfarin) and non-vitamin K antagonist oral
anticoagulants (NOAC, e.g., dabigatran, rivaroxaban,
apixaban, and edoxaban).
However, as far as we know, the use of OAC is sub-
optimal in China. In 2016, a prospective, multi-center
study conducted in China showed that 36.5% of NVAF
patients with CHA2DS2-VASc scores > 2 received OAC
(warfarin and NOAC) [10]. This study also reported that
a high proportion of AF patients (> 41%) used aspirin as
an anticoagulant [10]. In 2017, Yang surveyed the use of
OAC in AF patients in one hospital and concluded that
35.0% of patients received OAC, and 11.0% received
NOAC [11]. The reason for the low OAC usage may be
due to the fact that, although warfarin is widely used
among AF patients due to its effectiveness and low price,
it has a narrow therapeutic interval and needs frequent
monitoring and dose adjustments [9]. Additionally, some
NVAF patients with cardiovascular diseases chose anti-
platelet drugs (e.g., aspirin) to prevent embolism, which
may influence the use of OAC. Compared to VKAs,
NOAC was confirmed safer, slightly more effective and
more convenient [12–14]. However, studies have found
that high price is one of the main reasons that limit
patients’ use of NOAC [10, 11]. In order to reduce the
financial burden of patients, the Chinese medical insur-
ance has covered NOAC since 2017. As a result, patients
are paying less for NOAC. The current anticoagulant
therapy status among NVAF patients is unknown in
Jiangsu province, which is an economically developed
and densely populated area in China.
Methods
The aim, design and setting of the study
The aim of this multi-center, cross-sectional study was
to understand the current status of anticoagulant ther-
apy among Chinese patients with NVAF in Jiangsu prov-
ince. As this is an investigative study and based on the
reported rate of the OAC use which is put at 35% [10],
the sample size of the number of people to be surveyed
was estimated to be 972. In addition, taking into account
20% of the invalid questionnaire, 1167 patients should
be surveyed.
Patients were enrolled from the departments of
cardiology of seven hospitals in the different areas of
Jiangsu province from January to September in 2017.
Three of the hospitals were general tertiary hospitals
and four were local hospitals. Eligible patients were diag-
nosed as AF by electrocardiogram or ambulatory
electrocardiogram recorder according to the guideline of
the European Society of Cardiology (ESC) [9] and were ≥
18 years. Exclusion criteria were as follows: (1) patients
were with valvular disease or mechanical valve; (2)
rheumatic heart disease; (3) reversible AF (caused by
hyperthyroidism, acute myocardial infarction and so on);
(4) malignant tumors and blood diseases; (5) underwent
surgeries within three months.
Data collection
The patients’ sociodemographic characteristics (includ-
ing sex, age, payment, educational level), information on
AF (including type and duration of AF), medical history
(including hypertension, diabetes mellitus, hyperlipid-
emia, coronary heart disease, peripheral artery disease,
stroke, transient ischemic attack, myocardial infarction,
gastrointestinal bleeding, cerebral hemorrhage, impaired
renal/liver function) and use of any oral anticoagulants
were obtained by patient-reported questionnaire and
medical records. Investigators accepted uniform training,
guided patients to fill out the questionnaire and obtained
their medical history from medical records. Following
that, the CHA2DS2-VASc scores and HAS-BLED scores
were calculated for each patient based on their data.
The diagnosis of diabetes and hypertension were re-
ported by patients or collected from the medical records.
Diabetes was diagnosed according to the 1999 World
Health Organization criteria for diabetes [15]. It was
defined based on fasting capillary whole blood glucose
level (≥ 6.1mmol/L) or plasma glucose measurement
(FPG ≥ 7.0mmol/L and/or 2-h postprandial blood glucose
≥11.1mmol/L during an oral glucose tolerance test).
Hypertension was defined according to 2010 Chinese
guidelines for the management of hypertension [16],
which was described as systolic blood pressure (SBP) ≥
140mmHg, diastolic blood pressure (DBP) ≥ 90mmHg,
and use of antihypertensive medicine within two weeks.
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Risk stratification of stroke and bleeding
The CHA2DS2-VASc score was calculated for each pa-
tient to categorize the risk of stroke by assigning 1 point
each for age between 65 and 74 years, a history of hyper-
tension, diabetes mellitus, congestive heart failure,
vascular disease (CAD or peripheral artery disease), fe-
male sex and 2 points each for a history of stroke/TIA/
thromboembolism and age ≥ 75 years [9]. The total pos-
sible score was 9 points and higher scores indicated a
higher risk of stroke. According to the 2016 ESC guide-
line, the high risk of stroke is CHA2DS2VASc ≥ 2 for
males and CHA2DS2VASc ≥ 3 for females [9].
The HAS-BLED scores were also calculated for each
patient to categorize the risk of bleeding by assigning
1 point each for hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition, la-
bile INR, elderly (age > 65 years), drugs/alcohol con-
comitantly [9]. The total possible score on this scale
was also 9 points and score ≥ 3 indicated a high risk
of bleeding [9].
Outcome variable
The outcome variable was defined as whether patients
received OAC (NOAC or warfarin) or not (aspirin or no
medication), and it was coded as “1 = Yes” and “2 = No”
for multivariate logistic model.
Statistical analysis
Patients were divided into two groups according to the
use of anticoagulant: OAC (NOAC or warfarin) or no
OAC (aspirin or no medication). Categorical variables,
expressed as numbers and percentages, were compared
by Wilcoxon rank-sum test, Chi-square test. Univariate
analyses were used to screen significant variables.
Variables with p values < 0.1 and variables that may be
associated with anticoagulant therapy were included in
the multivariate analyses. The factors that make up
CHA2DS2-VASc score were adjusted as the confounding
variables in multivariate models. Subgroup analysis was
performed in patients with a history of stroke. Statistical
significance was considered at p < 0.05. All analyses
were performed using SPSS 20.0 software.
Results
A total of 650 patients were recruited from seven hospi-
tals in the study, while data from 593 patients (91.2%)
were analyzed (Fig. 1). Among eligible patients, 47.4%
were female and 21.9% had no medical insurance. The
majority of patients (87.2%) were older than 60 years and
more than half of the patients had a primary school edu-
cation or below. 56.3% of the patients had a duration of
AF which was less than 5 years; 72.8% of patients had a
high risk of stroke; 10.5% had a high risk of bleeding.
The prevalence of prior stroke was 11.1%. Detailed
demographics and medical history are shown in Table 1.
Among patients with a high risk of stroke, 11.1% were
on NOAC, 24.8% on warfarin and 30.6% on aspirin,
while 33.6% were not on medication. Of the patients
with low risk of bleeding, 10.5% were on NOAC, 24.7%
on warfarin, 28.6% on aspirin and 36.2% were not on
medication. For the patients whose HAS-BLED score
was ≥3, the corresponding numbers with respect to tak-
ing NOAC, warfarin, aspirin and no medication were
16.1, 22.6, 27.4 and 33.9%, respectively. The status of
Fig. 1 Flowchart of patients enrolled in the trial, Abbreviations: AF atrial fibrillation
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anticoagulant therapy based on the classification of
CHA2DS2-VASc score and HAS-BLED score are shown
in Table 2.
The results of the univariate analysis showed that vari-
ables including payment, age, duration of AF tended to
be related with anticoagulant therapy in all patients, and
payment, age, duration of AF and hypertension tended
to be related with anticoagulant therapy in patients with
a high risk of stroke. (Table 3).
Multivariate logistic regression analysis indicated that
self-paying, increasing age, duration of AF ≥5 years were
negatively associated with anticoagulant therapy in all
patients, whereas permanent AF was positively associ-
ated with anticoagulant therapy. Self-paying was the
strongest predictor of no anticoagulant therapy [odds
ratio (OR) 1.824, 95% confidence interval (CI) 1.136–
2.928], followed by the duration of AF ≥5 years (OR
1.505, 95% CI 1.035~2.189) and increasing age (OR
1.030, 95% CI 1.010~1.050). Patients with permanent AF
were more likely to receive anticoagulant therapy (OR
0.406, 95% CI 0.206~0.800). In the adjusted model,
increasing age was not significantly associated with
anticoagulant therapy. However, self-paying (OR 2.234,
95% CI 1.167~4.277) and increasing age (OR 1.055, 95%
CI 1.028~1.082) were associated with no anticoagulant
therapy in patients with a high risk of stroke, and these
factors were still significant in the adjusted model.
(Tables 4 & 5).
In subgroup analysis, increasing age was negatively as-
sociated with anticoagulant therapy among patients with
prior stroke (OR 1.075, 95% CI 1.016~1.139). Further-
more, self-paying was not only the influencing factor of
warfarin use, but also the influencing factor of NOAC
use (OR 1.816, 95% CI 1.089~3.028; OR 2.311, 95% CI
1.556~3.433, respectively). Details are shown in Tables 6
and 7.
Discussion
Anticoagulant therapy is the cornerstone of AF manage-
ment. The ESC guideline recommended OAC for pa-
tients with AF who are at high risk of stroke to prevent
stroke [9]. We investigated the OAC usage in a real-
world cohort among Chinese patients with NVAF in
Jiangsu province and found that the overall situation of
OAC usage does not appear optimistic, even in NVAF
patients at high risk of stroke. In our study, only 35.6%
of NVAF patients with different risks received OAC
which is lower than the data shown by the EURObserva-
tional Research Programme on Atrial Fibrillation Pilot
Survey, which found that 80.5% of AF patients with
CHA2DS2VASc scores ≥1 received OAC [17]. The
proportion of NVAF patients receiving warfarin and
NOAC were 24.5 and 11.1%, respectively, which are
both lower than the data presented by ORBIT-AF
study (71% warfarin) [18] and the ORBIT-AF II study
(71% NOAC) [19].
The 2016 ESC guideline states that aspirin is not rec-
ommended for antithrombotic therapy regardless of the
risk of stroke in patients with AF [9]. Although the rate
of aspirin usage in this study was lower than it in
another study (> 41%) [10], a considerable proportion of
patients (28.5%) still used aspirin as an anticoagulant. In
addition, 30.5% of patients with high risk of stroke were
Table 1 Demographic and clinical characteristics in patients
with NVAF n = 593
Variables Classification N (%)
Gender Female 281 (47.4)
Payment Self-paying 130 (21.9)
Age, years < 60 76 (12.8)
60~69 157 (26.5)
70~79 205 (34.6)
≥80 155 (26.1)
Education Primary school or below 316 (53.3)
Junior high school 145 (24.5)
Senior high school and above 132 (22.2)
AF type Paroxysmal 381 (64.3)
Persistent 172 (29.0)
Permanent 40 (6.7)
Duration, years < 5 335 (56.3)
Severity of symptom Asymptomatic 61 (10.3)
Mild 334 (56.3)
Moderate 169 (28.5)
Severe 29 (4.9)
Stroke Yes 66 (11.1)
Concomitant disease
Hypertension Yes 359 (60.5)
Diabetes mellitus Yes 118 (19.9)
Coronary heart disease Yes 138 (23.2)
Heart failure Yes 94 (15.8)
Vascular disease Yes 27 (4.6)
Hyperlipidemia Yes 38 (6.4)
Impaired renal/liver
function
Yes 29 (4.9)
HAS-BLED, score < 3 531 (89.5)
CHA2DS2-VASC, score Male: 0~2; female: 0~1 161 (27.2)
Male ≥3; female ≥2 432 (72.8)
Abbreviations: AF Atrial fibrillation, CHA2DS2-VASc Congestive heart failure,
hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic
attack, or thromboembolism, vascular disease, age 65–74 years,sex category
(female), HAS-BLED Hypertension, abnormal renal and/or liver function, stroke,
bleeding history or predisposition, labile international normalized ratio, elderly
(age > 65 years), drugs and/or alcohol concomitantly, NVAF Non-valvular atrial
fibrillation, TIA Transient ischemic attack
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on aspirin alone, which was much higher than the data
of the ORBIT-AF II study (8%) [19]. This might be be-
cause the patients enrolled in the study were mainly eld-
erly patients (about 60% of them were ≥ 70 years old)
who were commonly using aspirin for prevention of
thrombosis. Besides, patients with coronary heart disease
who usually take aspirin for treatment, and in this study
23.2% of NVAF patients had coronary heart disease. A
recent study in Thailand concluded that the administra-
tion of aspirin was one of the reasons for not prescribing
anticoagulants in the older population [20]. In addition,
more than half of the participating hospitals were local
hospitals and there may be gaps in medical resources
between hospital at different levels. For example, in pri-
mary hospitals, doctors may lack knowledge and under-
standing of new treatment regimens. However, doctors
have the responsibility to tell patients the importance of
anticoagulant therapy. In this regard, doctors in primary
hospitals should update their knowledge timely in order
to educate NVAF patients.
Another finding of the study is that the bleeding risk
did not influence the OAC use which is in line with ESC
guideline which indicates that a high level of HAS-BLED
score is not an excuse to withhold OAC [9]. However,
33.6% of patients with high risk of stroke did not take
any anticoagulants in this study, which is consistent with
Yang’s study in 2017 [11]. Namely, the high CHA2DS2-
VASC score was not associated with anticoagulant
therapy, which reminds us to focus on the phenomenon
that patients were not prescribed with OAC suitably ac-
cording to their risk stratification of stroke, and methods
of improving this condition including educational
programme should be put in place.
The multivariate logistic analysis showed that in the
adjustment model, self-paying, the duration of AF > 5
years was negatively associated with anticoagulant
therapy, whereas permanent AF was positively associated
with anticoagulant therapy in all patients. Among
patients with a high risk of stroke, self-paying and
increasing age were negatively associated with anticoagu-
lant therapy.
Age and payment
The relationship between old age and medication
adherence has been as an issue in different studies [10,
21–23]. A population-based retrospective cohort study
in Spain demonstrated that younger patients showed
poorer primary adherence [22]. However, some studies
concluded that old patients had poorer medication ad-
herence [10, 23], which is consistent with the results of
this study. One possible explanation is that older people
with AF commonly have other comorbidities. About
70% of patients in this study had comorbidity, and of
these, 31.4% of patients had two or more comorbidities,
which usually leads to polypharmacy, a condition known
to influence anticoagulant therapy [24]. In addition, phy-
sicians are inclined to overestimate the risk of bleeding
when an older patient has both a high risk of bleeding
and stroke [25, 26]. In the subgroup analysis, increasing
age was also negatively associated with anticoagulant
therapy among the patients with prior stroke. Palareti
et al. found that previous stroke history was an inde-
pendent risk factor for oral anticoagulants and blood
events [27]. Moreover, patients with stroke history usu-
ally have sequela which may limit them to visit doctors,
further influencing the OAC use.
Self-paying is a major factor associated with OAC use
in the study, especially with NOAC, which was also
found in another study [28]. Warfarin needs frequent
monitoring for INR, dose adjustment, drug or food in-
teractions and fares to the hospital [9], which limits pa-
tients use it. Currently in China, the medical insurance
could reimburse the cost of NOAC for inpatients. For
outpatients, 70% of cost could be reimbursed, and the
remaining 30% need to be paid at their own expense.
However, most of NVAF patients are outpatients, which
means that patients payments for NOAC remain high
(about $1740/y). Therefore, the economic burden can
explain the low OAC usage to some extent. In addition,
as older people usually have lower incomes, the old age
of the patients may strengthen the connection between
self-paying and no anticoagulant therapy. Thus, the au-
thorities providing insurance policy should pay attention
Table 2 Status of anticoagulant therapy among patients with NVAF at the different risk levels of stroke and bleeding
NOAC, n(%) Warfarin, n(%) Aspirin, n(%) No medication, n(%)
CHA2DS2-VASc
Male: 0~2; female: 0~1 18 (11.2) 38 (23.6) 37 (23.0) 68 (42.2)
Male ≥3; female ≥2 48 (11.1) 107 (24.8) 132 (30.5) 145 (33.6)
HAS-BLED
< 3 56 (10.5) 131 (24.7) 152 (28.6) 192 (36.2)
≥ 3 10 (16.1) 14 (22.6) 17 (27.4) 21 (33.9)
Abbreviations: CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism,
vascular disease, age 65–74 years, sex category (female), HAS-BLED Hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition,
labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, NOAC Non-vitamin K antagonist oral anticoagulant, NVAF Non-
valvular atrial fibrillation
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Table 3 Relationship between demographic, clinical characteristics and anticoagulant therapy in all patients and those with high
risk of stroke
Variables Classification All patients n(%) z/χ2 p value patients with high risk of
stroke n(%)
z/χ2 p value
OAC no OAC OAC no OAC
Gender Male 114 (37.5) 198 (63.5) 1.795 0.180 α 78 (35.8) 140 (64.2) 0.602 0.438 α
Female 88 (31.3) 193 (68.7) 69 (32.2) 145 (67.8)
Payment Self-paying 32 (24.6) 98 (75.4) 6.618 0.010 α 15 (21.1) 56 (78.9) 6.299 0.012 α
Medical insurance 170 (36.7) 293 (63.3) 132 (36.6) 229 (63.4)
Age < 60 31 (40.8) 45 (59.2) −3.017 0.003 β 11 (73.3) 4 (26.7) 24.304 0.000 β
60~69 57 (36.3) 100 (63.7) 35 (39.3) 54 (60.7)
70~79 81 (39.5) 124 (60.5) 68 (39.1) 106 (60.9)
≥80 33 (21.3) 122 (78.7) 33 (21.4) 121 (78.6)
Education Primary school or below 103 (32.6) 213 (67.4) −0.290 0.771 β 84 (32.7) 173 (67.3) 1.402 0.496 β
Junior high school 58 (40.0) 87 (60.0) 35 (39.3) 54 (60.7)
Senior high school and above 41 (31.1) 91 (68.9) 28 (32.6) 58 (67.4)
AF type Paroxysmal 122 (32.0) 259 (68.0) −1.697 0.090 β 82 (31.8) 176 (68.2) 2.298 0.317 β
Persistent 60 (34.9) 112 (65.1) 50 (35.7) 90 (64.3)
Permanent 20 (50.0) 20 (50.0) 16 (45.7) 19 (54.3)
Duration < 5 years 129 (38.5) 206 (61.5) 6.768 0.009 α 89 (38.2) 144 (61.8) 4.774 0.029 α
≥5 years 73 (28.3) 185 (71.7) 58 (29.1) 141 (70.9)
Symptom of severity Asymptomatic 28 (45.9) 33 (54.1) −0.951 0.342 β 20 (46.5) 23 (53.5) 4.143 0.246 β
Mild 108 (32.3) 226 (67.7) 77 (32.5) 160 (67.5)
Moderate 55 (32.5) 114 (67.5) 42 (31.6) 91 (68.4)
Severe 11 (37.9) 18 (62.1) 8 (42.1) 11 (57.9)
Hypertension Yes 129 (35.9) 230 (64.1) 1.686 0.194 α 115 (37.5) 192 (62.5) 5.565 0.018 α
No 72 (30.8) 162 (69.2) 32 (25.6) 93 (74.4)
Vascular disease Yes 7 (25.9) 20 (74.1) 0.802 0.371 α 18 (28.1) 46 (71.9) 1.166 0.280 α
No 194 (34.3) 372 (65.7) 129 (35.1) 239 (64.9)
Diabetes mellitus Yes 46 (39.0) 72 (61.0) 1.702 0.192 α 46 (40.4) 68 (59.6) 2.758 0.097 α
No 155 (32.6) 320 (67.4) 101 (31.8) 217 (68.2)
Coronary heart disease Yes 41 (29.7) 97 (70.3) 1.406 0.236 α 36 (31.6) 78 (68.4) 0.414 0.520 α
No 160 (35.2) 295 (64.8) 111 (34.9) 207 (65.1)
Heart failure Yes 36 (37.9) 59 (62.1) 0.537 0.464 α 30 (37.0) 51 (63.0) 0.402 0.526 α
No 155 (32.6) 320 (67.4) 117 (33.3) 234 (66.7)
Hyperlipidemia Yes 8 (21.1) 30 (78.9) 2.989 0.084 α 5 (20.0) 20 (80.0) 2.326 0.127 α
No 193 (34.8) 362 (65.2) 142 (34.9) 265 (65.1)
Stroke Yes 19 (28.8) 47 (71.2) 0.865 0.352 α 19 (29.2) 46 (70.8) 0.588 0.443 α
No 182 (34.5) 345 (65.5) 128 (34.9) 239 (65.1)
Impaired renal/liver function Yes 13 (44.8) 16 (55.2) 1.626 0.202 α 12 (44.4) 15 (55.6) 1.392 0.238 α
No 188 (33.3) 376 (66.7) 135 (33.3) 270 (66.7)
HAS-BLED, score < 3 180 (33.9) 351 (66.1) 0.062 0.803 α 125 (33.8) 245 (66.2) 0.068 0.794 α
≥3 22 (35.5) 40 (64.5) 22 (35.5) 40 (64.5)
CHA2DS2-VASc, score Male: 0~2; female: 0~1 56 (34.8) 105 (65.2) 0.062 0.804
α
Male ≥3; female ≥2 155 (35.9) 277 (64.1)
Abbreviations: AF Atrial fibrillation, CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years,diabetes mellitus, prior stroke, transient ischemic
attack, or thromboembolism, vascular disease, age 65–74 years, sex category (female), HAS-BLED Hypertension, abnormal renal and/or liver function,
stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, NOAC Non-
vitamin K antagonist oral anticoagulant
α: χ2-test; β: Wilcoxon rank-sum test
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to this health economics issue to help low income pa-
tients to improve OAC usage.
Duration and type of AF
Previous studies have shown that the rate of OAC use
has decreased over time [29]. Besides, the unsatisfactory
therapeutic effect also appears to influence adherence to
long-term medication use. In this study, compared to
those with the duration of AF < 5 years, patients who
had the duration of AF ≥ 5 years were less likely to re-
ceive anticoagulant therapy. Health education interven-
tions, such as regular educational programme and
mobile health technologies, can significantly improve
OAC use and drug adherence in patients with NVAF
[30, 31]. Therefore, it is necessary to timely evaluate
changes in patients’ medication adherence and regularly
provide health education for patients with NVAF.
Patients with permanent AF were more likely to re-
ceive anticoagulant therapy in this study, which is in line
with the study in 2016 by Wang et al. [32]. In 2012,
Chiang et al. reported that stroke rates were higher in
patients with persistent than paroxysmal AF, while these
were highest in patients with permanent AF [33]. The
guideline on AF management recommended OAC for
stroke prevention, irrespective of the type of AF [8].
Aronis et al. in 2016 [34] and Rizos et al. [35] in 2011 re-
ported that a significant proportion of episodes of stroke
in patients with AF occur in patients with a history of
Table 4 Factors associated with anticoagulant therapy in all patients and those with high risk of stroke (Multivariate logistic regression)
All patients patients with high risk of stroke
Variables B OR (95% CI) P value B OR (95% CI) P value
Gender, Female 0.210 1.234 (0.848~1.796) 0.272 0.043 1.044 (0.681~1.601) 0.844
Payment, Self-paying 0.601 1.824 (1.136~2.928) 0.013 0.884 2.234 (1.167~4.277) 0.015
Age (per 1 year increase) 0.029 1.030 (1.010~1.050) 0.003 0.053 1.055 (1.028~1.082) < 0.001
Education −0.180 0.835 (0.553~1.260) 0.391 −0.060 0.941 (0.565~1.568) 0.817
AF type, Permanent −0.902 0.406 (0.206~0.800) 0.009 −0.615 0.541 (0.253~1.157) 0.113
Duration, ≥5 years 0.409 1.505 (1.035~2.189) 0.033 0.286 1.332 (0.863~2.055) 0.196
Severity of symptom −0.003 0.997 (0.774~1.283) 0.979 0.057 1.059 (0.598~1.874) 0.845
HAS-BLED, score≥ 3 −0.316 0.729 (0.384~1.385) 0.334 −0.196 0.822 (0.446~1.516) 0.530
CHA2DS2-VASC, (per 1score increase) −0.117 0.890 (0.747~1.059) 0.190 −0.058 0.944 (0.736~1.210) 0.647
Hypertension 0.456 1.578 (0.966~2.578) 0.068
Abbreviations: AF Atrial fibrillation, CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or
thromboembolism, vascular disease, age 65–74 years, sex category (female), CI Confidence interval, HAS-BLED Hypertension, abnormal renal and/or liver function,
stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, OR Odds ratio
Table 5 Factors associated with anticoagulant therapy in all patients and those with high risk of stroke (Multivariate logistic regression)
All patients Patients with high risk of stroke
Variables B OR (95% CI) P value B OR (95% CI) P value
Gender, Female 0.185 1.203 (0.820~1.763) 0.345 0.091 1.096 (0.641~1.874) 0.739
Payment, Self-paying 0.555 1.742 (1.086~2.794) 0.021 0.835 2.305 (1.186~4.478) 0.014
Age (per 1 year increase) 0.024 1.024 (0.997~1.053) 0.085 0.084 1.087 (1.041~1.135) < 0.001
Education −0.108 0.897 (0.590~1.364) 0.612 −0.069 0.934 (0.555~1.572) 0.796
AF type, Permanent −0.857 0.424 (0.215~0.839) 0.014 −0.552 0.576 (0.264~1.255) 0.165
Duration, ≥5 years 0.386 1.471 (1.006~2.149) 0.046 0.286 1.332 (0.858~2.067) 0.202
Severity of symptom 0.132 1.141 (0.715~1.819) 0.580 0.043 1.044 (0.586~1.860) 0.884
HAS-BLED, score≥ 3 −0.339 0.712 (0.369~1.375) 0.312 −0.289 0.749 (0.364~1.540) 0.432
CHA2DS2-VASC,(per1score increase) −0.108 0.897 (0.713~1.130) 0.357 0.015 1.015 (0.750~1.374) 0.923
Hypertension 0.465 1.592 (0.933~2.717) 0.088
Adjustment variable: congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, orth romboembolism, vascular
disease, sex category (female)
Abbreviations: AF atrial fibrillation, CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or
thromboembolism, vascular disease, age 65–74 years, sex category (female), CI Confidence interval, HAS-BLED Hypertension, abnormal renal and/or liver function,
stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, OR Odds ratio
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paroxysmal AF, varying from 31 to 53%. In view of this,
physicians should pay more attention to patients with
paroxysmal or persistent AF.
Some limitations of this study must be considered.
Most of the data in the study was collected using the
self-reported questionnaire, in which the existence of
recall bias should be recognized, although this
method is a good way to investigate the use of anti-
coagulants among a large number of NVAF patients.
As a multi-center and cross-sectional study, the sam-
ple size was small, and the participants were only en-
rolled from seven hospitals in Jiangsu province.
Furthermore, psychosocial factors influencing the
OAC use were not considered which may limit the
interpretation of the results.
Conclusions
The results of this study showed that OAC was under-
used among Chinese NVAF patients in Jiangsu province,
especially in patients at high risk of stroke. Anticoagu-
lant therapy is positively associated with permanent AF
and negatively associated with self-paying, duration of
AF > 5 years. In order to improve the use of OAC, the
importance of anticoagulant therapy should be empha-
sised, and the economic situation of NVAF patients in
relation to anticoagulant therapy should be considered.
Abbreviations
AF: Atrial fibrillation; CHA2DS2-VASc: Congestive heart failure, hypertension,
age≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, and
sex (female); CI: Confidence interval; ESC: European society of cardiology; HAS-
BLED: Hypertension, abnormal renal/liver function (1 point each), stroke, bleeding
history or predisposition, labile international normalized ratio, elderly (> 65 years),
drugs/alcohol concomitantly (1 point each); NOAC: Non-vitamin K antagonist oral
anticoagulant; NVAF: Non-valvular atrial fibrillation; OAC: Oral anticoagulation;
OR: Odds ratio; TIA: Transient ischemic attack; VKAs: Vitamin K antagonists
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